Abstract
TUBB4A pathogenic variants are associated with a spectrum of neurologic impairments including movement disorders and leukodystrophy. With the development of targeted therapies, there is an urgent unmet need for validated tools to measure mobility impairment. Our aim is to explore gross motor function in a pediatric-onset TUBB4A-related leukodystrophy cohort with existing gross motor outcome tools. Gross Motor Function Measure-88 (GMFM-88), Gross Motor Function Classification System (GMFCS-ER), and Gross Motor Function Classification-Metachromatic Leukodystrophy (GMFC-MLD) were selected through face validity. Subjects with a confirmed clinical and molecular diagnosis of TUBB4A-related leukodystrophy were enrolled. Participants’ sex, age, genotype, and age at disease onset were collected, together with GMFM-88 and concurrent GMFCS-ER and GMFC-MLD. Performances on each measure were compared. GMFM-88 floor effect was defined as total score below 20%. A total of 35 subjects participated. Median performance by GMFM-88 was 16.24% (range 0-97.31), with 42.9% (n = 15) of individuals performing above the floor. GMFM-88 Dimension A (Lying and Rolling) was the best-performing dimension in the GMFM-88 (n = 29 above the floor). All levels of the Classification Scales were represented, with the exception of the GMFC-MLD level 0. Evaluation by GMFM-88 was strongly correlated with the Classification Scales (Spearman correlations: GMFCS-ER:GMFM-88 r = 0.90; GMFC-MLD:GMFM-88 r = 0.88; GMFCS-ER:GMFC-MLD: r = 0.92). Despite overall observation of a floor effect, the GMFM-88 is able to accurately capture the performance of individuals with attenuated phenotypes. GMFM-88 Dimension A shows no floor effect. GMFC-MLD shows a strong correlation with GMFCS-ER and GMFM-88, supporting its use as an age-independent functional score in TUBB4A-related leukodystrophy.
Original language | English |
---|---|
Pages (from-to) | 498-504 |
Number of pages | 7 |
Journal | Journal of Child Neurology |
Volume | 38 |
Issue number | 8-9 |
Early online date | 17 Jul 2023 |
DOIs | |
Publication status | Published - Aug 2023 |
Bibliographical note
Funding Information:The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AV, LA, and FG were supported by U54TR002823 from the NIH, NINDS, and NCATS. LAA supported by the NIH under Award Number K23NS114113. GB has received a Clinical Research Scholar Junior 1 award from the Fonds de Recherche du Quebec – Santé (FRQS) (2012-2016), New Investigator Salary Award from the Canadian Institutes of Health Research (2017-2022) and Senior Clinical Research Scholar award from the FRQS (2022-2025). FM is supported by the Edmond J. Safra Foundation.
Publisher Copyright:
© The Author(s) 2023.
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: AV, LA, and FG were supported by U54TR002823 from the NIH, NINDS, and NCATS. LAA supported by the NIH under Award Number K23NS114113. GB has received a Clinical Research Scholar Junior 1 award from the Fonds de Recherche du Quebec – Santé (FRQS) (2012-2016), New Investigator Salary Award from the Canadian Institutes of Health Research (2017-2022) and Senior Clinical Research Scholar award from the FRQS (2022-2025). FM is supported by the Edmond J. Safra Foundation.
Funders | Funder number |
---|---|
Edmond J. Safra Foundation | |
National Institutes of Health | |
National Institute of Neurological Disorders and Stroke | |
National Center for Advancing Translational Sciences | K23NS114113 |
National Center for Advancing Translational Sciences | |
Canadian Institutes of Health Research | 2022-2025, 2017-2022 |
Canadian Institutes of Health Research | |
Fonds de Recherche du Québec - Santé | 2012-2016 |
Fonds de Recherche du Québec - Santé |
Keywords
- GMFC-MLD
- GMFM-88
- gross motor
- leukodystrophy
- TUBB4A